体质 FMT 传递表型的「剂量-反应」曲线标定:供体菌群移植量/多样性与受体偏颇表型强度(体质量表客观化指标/代谢终点)的关系是单调、平台还是倒U

Written by

in

Language

Evidence level: C

若中医「体质偏颇」有一部分由肠道菌群承载,那么它就是可传递、可滴定、可标定曲线的量——问题只剩:这条曲线长什么样。

正文(1000-1500字)

中医体质学把「体质」当作相对稳定的禀赋,五行归类里的「木火土金水之人」本质上是在给个体差异建模。而现代微生物组学给这个模型补了一块地基:相当一部分代谢与行为表型,是可以随菌群整体「过继」的。小鼠实验里,把「消沉」供体的菌群移植给无菌小鼠,受体出现抑郁样行为,中介通路被定位到内源性大麻素系统(PMID 33311466);炎症性肠病模型中甚至观察到表型的双向逆向转移(PMID 30593419);把老龄小鼠菌群移植给年轻健康小鼠,受体的瘦体重显著下降(PMID 37475479)。肠道传输时间这类深度生理表型则不能经菌群转移(PMID 42125246)——传递是真实的,但是表型特异、有边界的。

这就把我们引向一个从未被认真标定过的问题:传递的「量」怎么算?剂量-反应曲线至少有三种可能形状。第一种是单调上升:供体菌群移植量与多样性越高,受体偏颇表型(按体质量表客观化指标或代谢终点量化)越强,意味着体质干预可以靠加量无限逼近目标。第二种是平台型:受体定植生态位有饱和上限,超过某个剂量后多余菌群只是穿肠而过,曲线进入平台——这种情况下「最小有效剂量」才是关键参数。第三种是倒U型:过量移植触发受体的定植抵抗与免疫排斥,反而压低传递效率。现有证据对这个裁决是缺席的:人体 FMT 研究里剂量通常以移植次数、制剂形式和供体多样性间接代理,肥胖合并 2 型糖尿病受试者的 24 周双盲 RCT 显示定植程度与制剂路径相关,但没有做剂量梯度(PMID 33785557);C. diff 感染 FMT 失败预测因子的更新 meta 分析(PMID 35050941)与成功决定因素综述(PMID 37167953)都承认剂量学是薄弱环节;肥胖与代谢综合征的系统综述(PMID 31557953)和 RCT 伞形综述(PMID 35832379)的结论同出一辙。

动物侧同样没有现成答案。移植方法的比较研究显示,不同传递方式的菌群转移效率与疾病表型影响差异显著(PMID 36380056);定植失败不仅让转移无效,还会加重 DSS 结肠炎模型的损伤(PMID 39812347)——这提示曲线左端存在「不足剂量」的独立风险区,进一步提高了标定曲线形状的价值。小鼠菌群移植操作规范也已发布(PMID 34621688),剂量梯度实验有现成方法学底座。

具体裁决设计:设四个剂量梯度(10⁶、10⁷、10⁸、10⁹ CFU),供体统一为同一高偏颇表型个体池;受体为同批同源无菌/抗生素清除小鼠,随机分臂;终点设两层——体质量表的客观化替代指标(体质分型的量表得分映射到可测体征组合)与代谢终点(胰岛素耐受、脂质谱、粪代谢组);每个受体在移植前、后 2 周、6 周复评三次;曲线拟合同时放单调、平台(Hill 方程)与二次项(倒U)三个候选模型,用 AIC 与预注册假设检验裁决;最小有效剂量以「效应量达对照组 50% 的最低梯度」定义。证伪条件:若三个模型在预注册的样本量下 AIC 差值均小于 2,或四个梯度的效应量置信区间完全重叠,则判定「体质偏颇的菌群承载部分对剂量不敏感」,该路径降级为定性假说。

对易学-科学桥接的意义在于:五行体质模型若要走出「类型学描述」,剂量-反应曲线是它进入定量科学的标准门票——曲线形状直接决定体质调理是「累积工程」(单调)、「阈值工程」(平台)还是「适度工程」(倒U),三者的实践含义完全不同。

证据与局限

已验证: 菌群可传递特定代谢与行为表型(PMID 33311466、30593419、37475479);传递具表型特异性,非全能(PMID 42125246);人体 FMT 定植程度受制剂路径影响(PMID 33785557)。
部分验证: 不同移植方法的传递效率差异(PMID 36380056);定植充分性影响结局方向(PMID 39812347、35050941)。
待验证: 剂量-反应曲线的具体形状(单调/平台/倒U);最小有效剂量是否存在;体质量表客观化指标能否作为菌群传递的敏感终点;人类体质偏颇与菌群承载成分的对应比例。

相关阅读

L1 网络状态:该主题尚未进入 L1 对应网络——CORRESPONDENCE_NETWORK.md 与 EDGE_TABLE_science-yixue.md 中 FMT/菌群移植/体质-剂量 相关检索零命中(NETWORK 仅第 73 行有「体质分型|量表|个体差异的调节变量」泛化条目,剂量-反应条目均属 E-060 电针频率、E-004 脾收缩等无关边)。
证据等级: C
参考文献: PMID 33311466, PMID 30593419, PMID 37475479, PMID 42125246, PMID 33785557, PMID 35050941, PMID 37167953, PMID 31557953, PMID 35832379, PMID 36380056, PMID 39812347, PMID 34621688

证据等级:A=有PubMed直接支撑,B=科学类比/间接证据,C=传统文化共识/初步探索


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Calibrating the \”dose-response\” curve of phenotype transmission via FMT: monotonic, plateau, or inverted-U relationship between donor microbiota transplant dose/diversity and re…

Evidence level: C

If a portion of the traditional consensus notion of “body constitution bias” is carried by the gut microbiota, then it becomes a transmissible, titratable, and curve-calibratable quantity—the remaining question is simply what shape this curve takes.

Body (1000–1500 words)

Yijing Studies and Feng Shui both treat the human body as a patterned system that can be modeled through structural analogy. In Yijing Studies, the Five Phases (Yin-Yang framework of Wood, Fire, Earth, Metal, Water) classify individuals into “Wood-person, Fire-person, etc.” not as symbolic types but as a way to map individual variation. This modeling approach gains a foundational layer from modern microbiome science: a substantial portion of metabolic and behavioral phenotypes can be transferred en bloc via the gut microbiota.

In mouse experiments, transplanting the microbiota of a “depressed” donor into germ-free recipients induced depressive-like behavior, with the endogenous cannabinoid system identified as the mediating pathway (PMID 33311466). In colitis models, bidirectional reversal of phenotypes was observed (PMID 30593419). Transplanting microbiota from aged mice into young healthy mice led to a significant decline in lean mass in recipients (PMID 37475479). However, deep physiological traits such as gut transit time do not transfer via microbiota (PMID 42125246)—transfer occurs, but phenotypes are specific and bounded.

This leads us to an under-specified question: How is the “amount” of transfer quantified? Dose–response curves can take at least three shapes. First, monotonic increase: higher donor microbiota quantity and diversity yield stronger recipient phenotypic bias (measured via objective somatic markers or metabolic endpoints), implying that Yijing-style intervention can approach targets by increasing dose. Second, plateau: recipient ecological niches saturate; beyond a threshold, extra microbiota pass through without effect, making “minimum effective dose” the key parameter. Third, inverted-U: excessive transfer triggers colonization resistance and immune rejection, reducing efficiency.

Current evidence is absent on this decision. In human FMT studies, dose is usually proxied by transplant frequency, formulation, and donor diversity. A 24-week double-blind RCT in obese patients with type 2 diabetes found that colonization level correlated with formulation route, but no dose gradient was tested (PMID 33785557). Updated meta-analyses of C. diff FMT failure predictors (PMID 35050941) and success determinants (PMID 37167953) both acknowledge dosimetry as a weak link; systematic reviews of obesity and metabolic syndrome (PMID 31557953) and RCT umbrella reviews (PMID 35832379) reach the same conclusion.

Animal studies offer no ready answer either. Comparative transfer methods show significant differences in efficiency and disease phenotype impact (PMID 36380056). Colonization failure not only nullifies transfer but exacerbates damage in DSS colitis models (PMID 39812347)—suggesting a distinct “under-dose” risk zone on the left of the curve, further underscoring the value of defining the dose–response shape. Standardized mouse microbiota transplant protocols now exist (PMID 34621688), and dose-gradient experiments have established methodological foundations.

Proposed experimental design: four dose gradients (10⁶, 10⁷, 10⁸, 10⁹ CFU), with donors drawn from the same pool of high-bias phenotype individuals; recipients are germ-free or antibiotic-cleared mice from the same cohort, randomized across arms. Endpoints include two layers: (1) objective somatic markers derived from the Yijing-style somatic scale (mapping scale scores to measurable sign-combinations) and (2) metabolic endpoints (insulin tolerance, lipidome, fecal metabolome). Each recipient is reassessed at baseline, 2 weeks post-transplant, and 6 weeks post-transplant.

Curve fitting simultaneously tests three candidate models: monotonic, plateau (Hill equation), and quadratic (inverted-U). Model selection uses AIC and pre-registered hypothesis testing. Minimum effective dose is defined as the lowest gradient achieving 50% of the control group’s effect size. Falsification criteria: if, under pre-registered sample sizes, AIC differences among the three models are all <2, or if effect-size confidence intervals across the four gradients completely overlap, we conclude that “the microbiota-borne component of Yijing-style phenotypic bias is dose-insensitive,” downgrading this pathway to a qualitative hypothesis.

The bridge between Yijing Studies and science lies here: if the Five Phases model is to move beyond typological description, the dose–response curve becomes its standard ticket into quantitative science. The curve’s shape directly determines whether Yijing-style regulation is an “accumulative engineering” (monotonic), a “threshold engineering” (plateau), or a “moderate engineering” (inverted-U)—each with distinct practical implications.

Evidence and Limitations

Verified: Microbiota can transmit specific metabolic and behavioral phenotypes (PMID 33311466, 30593419, 37475479); transmission exhibits phenotypic specificity rather than universality (PMID 42125246); human fecal microbiota transplantation (FMT) colonization levels are influenced by formulation route (PMID 33785557).
Partially Verified: Differences in transmission efficiency across transplantation methods (PMID 36380056); sufficiency of colonization affects outcome directionality (PMID 39812347, 35050941).
Pending Verification: Specific shape of dose-response curves (monotonic/platform/inverted-U); existence of minimum effective dose; whether body mass index objective metrics can serve as sensitive endpoints for microbiota transmission; correspondence ratio between human constitutional predispositions and microbiota compositional components.

Related Reading

L1 network status: This topic has not yet entered the L1 correspondence network. Zero hits were found in CORRESPONDENCE_NETWORK.md and EDGE_TABLE_science-yixue.md for queries related to FMT, microbiome transplantation, and constitution-dose relationships. The NETWORK file contains only a generalized entry on line 73 regarding “constitution typology | scales | moderators of individual differences,” while dose-response entries belong to unrelated edges E-060 (electroacupuncture frequency) and E-004 (spleen contraction).
Evidence level: C
References: PMID 33311466, PMID 30593419, PMID 37475479, PMID 42125246, PMID 33785557, PMID 35050941, PMID 37167953, PMID 31557953, PMID 35832379, PMID 36380056, PMID 39812347, PMID 34621688

Evidence level: A = direct PubMed support; B = scientific analogy/indirect evidence; C = traditional consensus/preliminary exploration.


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *